Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 5
Submit an article Journal homepage
4
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Patent Update Cardiovascular & Renal: Treatments for myocardial ischaemia

Annette M Doherty Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA
, PhD
Pages 531-542 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • YANAGISAWA M, KURIHARA H, KIMLTRA 5, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, MASAIU T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Land.) (1988), 332, 411–415.
  • HAYNES WG, DAVENPORT AP, WEBB DJ: Endothelin: progress in pharmacology and physiology. Trends Phar-macol. Sci. (1993) 14, 225–228. Meeting report from 3rd International Conference on Endothelin, Houston, Texas, USA, February 1993.
  • SCHOMISCH-MORAVEC C, REYNOLDS EE, S rEWART RW, BOND M: Endothelia is a positive inotropic agent in human and rat heart in MM. Biochem. Biophys. Res. Commun. (1989) 159: 14–18.
  • STEWART DJ, KUBAC G, COSTELLO KB, CERNACEK P:Increased plasma endothelia-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. (1991) 18: 38–43.
  • TOMODA H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am. Heart]. (1993) 125: 667–672.
  • RAY SG, MCMURRAY JJ, MORTON JJ, DARGIE HJ: Circulat-hag endothelin in acute ischaemic syndromes. Br. Heart J. (1992) 67: 383–386.
  • TSUJI S, SAWAMURA A, WATANABE H, TAICIHARA K, PARK S-E, AZUMA J: Plasma endothelin levels during myocar-dial ischaemia and reperfusion. Life Sci. (1991) 48: 1745–1749.
  • LIU J, CASLEY DJ, NAYLER WG: Ischaemia causes exter-nalization of endothelin-1 binding sites in rat cardiac membranes. Biochem. Biophys. Res. Commun. (1989) 164: 1220–1225.
  • STAWSKI G, OLSEN UB, GRANDE P: Cytotoxk effect of endothelin-1 during simulated' ischaemia in cultured rat myocytes. Eur. J. Pharmacol. (1991) 201: 123–124.
  • SAITO T, FUSHIMI E, ABE T, KIMURA Y, TAKAHASHI K, KUDO Y, NAKAGOMI A, MIURA M: Augmented contrac- tile response to endothelin and blunted endothelium-dependent relaxation in post-ischaemic reperfused coronary arteries. Jpn. Circ. J. (1992) 56: 657–670.
  • MORROW JA, FORMAN MB, MURRAY JJ: Enhanced en- dothelin production during myocardial ischaemia stimulates adenosine release from neutrophils: a pos-sible protective mechanism against reperfusion. J. Am. Coll. Cardiot (1992) 19 (3, SuppL A): 131A. WATANABE T, SUZUKI N, SHIMAMOTO N, FUJINA M. IMADA, A: Endothelin in myocardial infarction. Nature (1990) 344: 114.
  • IHARA M, FUKURODA T, SAEKI T, NISHIKIBE M, KOJIRI K,SUDA H, YANO M: An endothelin receptor (ETA) antago-nist isolated from streptomyces tnisakiensis. Biochem. Biophys. Res. Commun. (1991) 178: 132–137.
  • ISHIKAWA K, FUICAMI T, NAGASE T, FUJITA K, HAYAMAT, NIYAMA K, MASE T, IHARA M, YANO M.: Cyclic pen-tapeptide endothelin antagonists with high ETA selec-tivity, potency and solubility-enhancing modifications. J. Med. Chem. (1992) 35: 2139–2142.
  • DOUGLAS SA, ELLIOTT JD, OHLSTEIN Eli: Regional vaso-dilation to endothelin-1 is mediated by a non-ETA re-ceptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynarnir responses. Eur. j Pharma-col. (1992) 221: 315–324
  • IHARA M, ISHIKAWA K, FUKURODA T, SAEKI T, FUNABASHI K, FUKAMI T, SUDA H, YANO M: In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor.]. Cardiovasc. Pharmacol. (1992) 20 (Suppl 12): S11–S14.
  • GROVER GJ, SLEPH PG, FOX M, TRIPPODO NC: Role ofendothelin-1 and big endothelin-1 in modulating coro-nary vascular tone, contractile function and severity of ischaemia in rat hearts. J. Pharmacol. Exp. 7ber. (1992) 263(3): 1074–1082.
  • MCMURDO L; THIEMERMANN C.; VANE JR: The en-dothelin ETA receptor antagonist, FR 139317, does not reduce infarct size in a rabbh model of acute myocardial ischaemia and reperfusion. Br. J. Pharmacol. (1993), Proceedings Supp. (July) 1301'.
  • SOGABE K, NIREI H, SHOUBO M, NOMOTO A, AO S,NOTSU Y, ONO T: Pharmacological profile of FR 139317, a novel, potent endothelin ETA receptor antagonist. J. Pharmacol. Exp. 7her. (1993) 264 (3): 1040–1046.
  • KIICUCHI T, ICUBO K, OHTAKI T, SUZUKI N, ASAMI T, SHIMAMOTO N, WAKIMASU M, FUJIN° M: Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelia antagonists with no selectivity for either receptor subytpe ETA or ETB. J. Med. Chem. (1993) 36: 4087–4093.
  • AKIYAMA H, INAGAIC.1 Y, KASHIWABARA T, OHTA H, FUKUSHIMA H, NISHIKORI K: Endothelin receptor bind-ing affinity and biological activity of a novel endothelin analog, 10ET-011. Jpn.J. Pharmacol. (1992) 58 (SuppL 1): 336P.
  • CODY WL, DOHERTY AM, HE pc, DEPUE PL, RAPUNDALOST, HINGORANI GA, MAJOR TC, PANEK RE, DUDLEY DT, HALEEN SJ, LADOUCEUR D, HILL KE, FLYNN MA, REYNOLDS EE: Design of a functional hexapeptide an-tagonist of endothelin. J. Med. Chem . (1992) 35:3301–3303.
  • CODY WL, DOHERTY AM, HE pc, DEPUE PL, WAITE LA,TOPLISS JG, HALEEN SJ, LADOUCEUR D, HILL KE, FLYNN MA, REYNOLDS EE: The rational design of a highly potent combined ETA and ET s receptor antagonist (PD 145065) and related analogs. Med. Chem. Res. (1993) 3:154–162.
  • DOHERTY AM, CODY WL, HE JX, DEPUE PL, CHENG X-M,WELCH KM, FLYNN MA, REYNOLDS EE, LADOUCEUR DM, DAVIS LS, KEISER JA, HALEEN SJ: In vitro and in vivo studies with a series of hexapepticle endothelin antago-nists. J. Cardiovasc. Pharmacol., (1993) 22\(SuppL 8):S98–S102.
  • FUJIMOTO M, MIHARA S-I, NAJAJIMA S, UEDA M, NAKA- MURA M, SAKURAI K: A novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. FEBS Lett. (1992) 305: 41–44.
  • MIHARA S, FUJIMOTO M: The endothelin ETA receptor- specific effect of 50-234, a non-peptide endothelin an-tagonist. Eur.J. Pharmacol. (1993) 246: 33–38.
  • OHASIII H, AKIYAMA H, NISHIKORI K, MOCHIZUKI J-I: Asterric add, a new endothelia binding inhibitor. J. Antibiot. (1992) 45(10):1684–1685.
  • CLOZEL M, BREU V, BURRI K, CASSAL J-M, FISCHLI W,GRAY GA, HIRTH G, LOFFLER B-M, MOLLER M, NEIDHARTW, RAMUZ H: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365:759–761.
  • MUGRAGE B, MOLITERNI J, ROBINSON L, WEBB RE SHEITY SS, LIPSON ICE, CHIN MH, NEALE R, CIOFFI C: CGS 27830, A potent nonpeptide endothelin receptor an-tagonist. Biootg. Med. Chem. Lett. (1993) 3:2099–2104.
  • STEIN PD, HUNT JT, FLOYD DM, MORELAND S, DICKIN-SON KEJ, MITCHELL C, LIU EC-K, WEBB ML, MURUGESAN N, DICKEY J, MCMULLEN D, ZHANG R, LEE VG, SERAFINO R, DELANEY C, SCHAEFFER TR, KOZLOWSKI M: The dis-covery of sulfonamide endothelia antagonists and the development of the orally active ETA antagonist 5-(Di-methyl amino)-N-(3,4-dimethy1-5-isoxazoly0-1-naph-thalene sulfonamide J. Med. Chem. (1994) 37:329–331.
  • ROUX SP, CLOZEL M, SPRECHER U, GRAY G, CLOZEL JP:Ro 47203, a new endothelia receptor antagonist re- verses chronic vasospasm experimental subarachnoid hemorrhage. Circulation (1993) 4\(Part 2, Supplement)-.1–170.
  • DOCHERTY K, STEINER DF: Post-translational proteoly-sis in polypeptide hormone biosynthesis. Annu. Rev. Physiol. (1982) 44625–638.
  • HARRIS RB: Processing of pro-hormone precursor pro-teins. Arch. Biochem. Biophys. (1989) 275:315–333.
  • ICASHIWABARA T, INAGAKI Y, OHTA H, 1WAMATSU A, NOMIZU M, MORITA A, NISHIKORI K: Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEM. Lett. (1989) 247:73–76.
  • KIMURA S, KAYSUYA Y, SAWAMURA T, SHINMI 0, SUGITAY, YANAGISAWA M, GOTO K, MASAKI T: Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: struc-ture-activity relationships of big endothelin-1. Cardiovasc. Pharmacol. (1989) 13:S5–S7.
  • OPGENORTH TJ, WU-WONG JR, SHIOSAKI K: Endothelin-converting enzymes. FASEB. J. (1992) 6:2653–2659.
  • POWERS JC, HARPER JW: Inhibitors of metalloproteases. In: Proteinase Inhibitors (1986). BARRETT AJ, SALVESEN G (Eds.) Elsevier, Amsterdam, Chapter 6.
  • VEMULAPALLI S, WATKINS RW, BROWN A, COOK J, BER-NARDINO V, CHIU PJ: Disparate effects of phosphorami-don on blood pressure in SHR and DOCA-salt hypertensive rats. Life. Sci. (1993) 53:783–793.
  • MCMAHON EG, PALOMO MA, BROWN MA, BERTENSHAW SR, CARTER JS: Effect of phosphoramidon (endothelia converting enzyme inhibitor) and BQ-123 (endothelia receptor subtype A antagonist) on blood pressure in hypertensive rats. Am. J. Hypertension. (1993) 6:667–673.
  • NIICAM SS, AHN K, PAN S, BENINGO K, HALEEN S, LADOUCEUR D, DOHERTY AM: Studies on the phospho-rus-containing inhibitors of endothelin converting en-zyme. MEDI 57, 206th ACS meeting, Chicago (August 1993).
  • BERTENSHAW SR, ROGERS RS, STERN MK, NORMAN BH, MOORE WM, JEROME GM, BRA_NSON LM, MCDONALD JF, MCMAHON EG, PALOMO MA: Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor po-tency. J. Med. Chem. (1993) 36:173–176.
  • BERTENSHAW SR, TALLEY JJ, ROGERS RS, CARTER JS, MOORE WM, BRANSON LM, KOBOLDT CM: Thiol and hydroxamic add containing inhibitors of endothelin converting enzyme. Biootg. Med. Chem. Len . (1993) 3:1953–1958.
  • SHIOSAICI K, TASKER AS, SULLIVAN GM, SORENSEN BK, VON GELDERN TW, WU-WONG JR, MARSELLE CA, OP-GENORTH TJ: Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme Identified Indic rat lung. j. Med. Chem. (1993) 36: 468–478.
  • OKADA K, ARMY, HATA M, MATSUYAMA K, YANO M: Big endothelin-1 structure important for specific process-ing by endothelin-converting enzyme of bovine endo-thelial cells. Eur. J. Biochem. (1993) 218: 493–498.
  • In: Potassium Channel Modulators (1992). WESTON AH,HAMILTON TC (Eds.), Blackwell Scientific Publications, Ox-ford. Extensive review of potassium channel modulation.
  • NOMA A: ATP-regulated K+ channels in cardiac muscle. Nature (1983) 305:147–148.
  • ATWAL KS: Modulation of potassium channels by or-ganic molecules. Med. Res. Rev. (1992) 12:569. Review of known potassium channel openers.
  • RICHER C, PRATZ J, MULDER P, MONDOT S, GIUDICELLI JF, CAVERO I: Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci. (1990) 47: 1693–1705. Review.
  • TOSAIU A, SZERDAHELYI P, ENGELMAN RM, DAS DK:Potassium channel openers and blockers: do they pos-sess proarrhythrnic or antiarrhythm c activity in is-c.haemic and reperfused rat hearts? J. Pbarmacol. Exp. 7her. (1993) 267 (3): 1355–1362. Arrhythmic effects.
  • ATWAL KS, GROVER GJ, AHMED SZ, FERRARA FN, HARPERTW, KIM KS, SLEPH PG, DZWONCZYK S, RUSSELL AD, MORELAND S, MCCULLOUGH JR, NORMANDIN DE: Cardioselective anti-ischaemk ATP-sensitive potassium channel openers. J. Med. Chem. (1993) 36: 3971–3974. Novel class of potassium channel openers.
  • PIROI i B, TULLIO P, LEBRUN P, ANTOINE M-H, FON-TAINE JU, MASEREEL B, SCHYNTS M, DUPONT L, HER CHUELZ A, DELARGE J:3-(Alkylamino)-411-pyrido[4,3-4-1,2,4-thiadiazine 1,1-Dioxides as powerful inhibitors of Insulin release from rat pancreatic B-cells: A new class of potassium channel openers? J. Med. Chem. (1993) 36: 3211–3213.
  • GADWOOD RC, KAMDAR By, CIPKUS DUBRAY LA, WOLFEML, SMITH MP, WATT W, MIZSAK SA, GROPPI VE: Synthe-sis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers. J. Med. Chem. (1993)36: 1480–1487.
  • MANLEY PW, QUAST U, ANDRES H, BRAY K: Synthesis of and radioligand binding studies with a tritiated pi-nacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers. J. Med. Chem. (1993) 36: 2004–2010.
  • THORNTON JD, THORNTON CS, STERLING DL, DOWNEYJM: Blockade of ATP-Sensitive potassium channels in-creases infarct size but does not prevent precondition-ing in rabbit hearts. Circulation Research (1993) 72:44–49.
  • GUBIN J, DE VOGELAER H, INION H, HOUBEN C, LUC- CHETTI J, MAHAUX J, ROSSEELS G, PEIREN M, CLINET M, POLSTER P, CHATELAIN P: Novel Heterocyclic analogues of the potent class of calcium channel blockers 1-[[4-aminoalkoxy)phenyl]sulfonyllindolizines. J. Med. Chem. (1993) 36: 1425–1433.
  • COLLIS MG, HOURANI SMO: Adenosine receptor sub-types. Trends Pharmacol. Sci. (1993) 14: 360–366.
  • SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J,JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1993) 90: 10365–10369.
  • LINDEN J, TAYLOR HE, ROBEVA AS, TUCKER AL, STEHLEJH, RIVICEES SA, FINK JS, REPPERT SM: Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol. Phar-macol. (1993) 44: 524–532.
  • TUCKER AL, LINDEN J: Cloned receptors and cardiovas-cular responses to adenosine. Cardiovasc. Res. (1993) 27: 62–67.
  • VAN GALEN PJM, STILES GL, MICHAELS G, JACOBSON KA:Adenosine Al and A2 receptors: Structure function relationships. Med. Res. Rev. (1992) 12:423–471.
  • CONTI A, MONOPOLI A, GAMBA M, BOREA PA, ONGINI E: Effects of selective At and A2 Adenosine Receptor Agonists on Cardiovascular Tissues. Arch. Pharmacol. (1993) 348: 108–112.
  • LASLEY RD, MENTZER, JR. RM: Adenosine improves re-covery of postischaemic myocardial function via an adenosine At receptor mechanism. Am.J. Physiol. (1992) 263:H1460–H1465.
  • MULLANE K: Acadesine: the prototype adenosine regu-lating agent for reducing myocardial ischaemic injury.Cardiovascular Res. (1993) 27:43–47.
  • TSUCHIDA A, LIU GS, MULLANE K, DOWNEY JM: Acades-ine lowers temporal threshold for myocardial infarct size limiting effect of preconditioning. Cardiovascular Res. (1993) 27:116–120.
  • PAN W, MULLANE K, YOUNG M: Anti-ischaemic activity of the novel adenosine regulating agent, GP-1-468, in a canine model of stable angina. FASEB J. (1993) 7:A119.
  • SEIGFREID MR, ERHARDT J, RIDER T, MA X-L, LEFER AM:Cardioprotection and attenuation of endothelial dys-function by organic nitric oxide donors in myocardial ischamnia-reperfusion. J. Pharmacol. Exp. 7ber. (1992) 260(2):668–675.
  • LEPER AM, TSAO PS, LEPER DJ, MA X-L: Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischaemia. FASEB J. (1991) 5:2029–2034.
  • FLAHERTY JT, BECKER LC, BULICLEY BIT, WEISS JL, GER-STENBLITH G, KALLMAN M, SILVERMAN KJ, WEI JY, prrr B, WEISFELDT ML: A randomized prospective trial of Intravenous nitroglycerin in patients with acute myo-cardial infarction. Circulation (1983) 68:576–588.
  • BECKMAN JS, BECKMAN 1W, CHEN J, MARSHALL PA, FREEMAN BA: Apparent hydroxyl radical production by peroxynitrite:Itnplications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA (1990) 87:1620–1624.
  • SIMPSON PJ, TODD RF, FANTONE JC, MICKELSON JK, GRIFFIN, JD, LUCCHESI BR: Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (Anti-Mol, Anti-CD11b) that inhibits leuko-cyte adhesion.]. Clin. Invest. (1988) 81:624–629.

References to Datent literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.